In addition, the companies also entered two other influenza-related, non-exclusive license agreements and a sponsored research agreement.
As per the deal, Alios will sponsor collaborative research at the University of Hong Kong, as Versitech is its technology transfer company.
Alios BioPharma founder and CEO Lawrence M Blatt said the compounds and technology derived from this deal would provide novel therapeutic options to help in the improvement of influenza virus-infected patients.